Why the study?
Do ACE inhibitors reduce the development of end-stage renal disease in patients with nondiabetic renal disease compared to other antihypertensive agents?
Population
1,594 patients from 10 randomized studies with nondiabetic renal disease
Comparison
Angiotensin-converting enzyme (ACE) inhibitors vs Other antihypertensive agents
Design
Meta-analysis
Follow-up
at least 1 year
Authors
Loading...
ACE inhibitors should be prioritized to reduce ESRD risk in nondiabetic renal disease; reinforces first-line role from pooled RCT data.
Do ACE inhibitors reduce the development of end-stage renal disease in patients with nondiabetic renal disease compared to other antihypertensive agents?
ACE inhibitors are more effective than other antihypertensive agents in reducing the progression to end-stage renal disease in patients with nondiabetic renal disease.
Ioannis Giatras (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: